Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.58 |
| ▸ | TUBB | P07437 | 2/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.58 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.58 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.58 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.58 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.58 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.58 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.58 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.58 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.58 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.58 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30621782 | 1.00 | EGFR (0.68) | EGFRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL15334880 | 0.94 | EGFR (0.61) | EGFRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL786740 | 0.92 | EGFR (0.57) | EGFRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL723275 | 0.82 | HDAC3 (0.55) | EGFRHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL786505 | 0.82 | TUBB1 (0.60) | EGFRTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL723686 | 0.81 | KDM1A (0.59) | EGFRHDAC3HDAC1HDAC7HDAC8 | |
| Hydrochloric Acid SCHEMBL722657 | 0.81 | HDAC3 (0.54) | EGFRHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL721855 | 0.81 | HDAC3 (0.54) | EGFRHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL721918 | 0.81 | HPGDS (0.54) | HDAC3HDAC1HDAC7HDAC8HDAC6 | |
| SCHEMBL725160 | 0.81 | EGFR (1.00) | EGFRTUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| EP-3793549-A1 | COMPOUNDS FOR TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND OVARIAN CANCER | University of Tennessee Research Foundation (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3793548-A1 | COMPOUNDS FOR TREATMENT OF PANCREATIC CANCER | University of Tennessee Research Foundation (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2021041744-A1 | RYL BENZOYL IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF LUNG CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2021-03-04 | — | — | WO | disclosed |
| EP-2608671-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Gtx, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027481-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
| WO-2011109059-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | EGFR 964/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | EGFR 964/4885TUBB4A 296/4885TUBB 213/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | EGFR 964/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | EGFR 964/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | EGFR 964/4885TUBB4A 296/4885TUBB 213/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | EGFR 964/4885TUBB4A 296/4885TUBB 213/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | EGFR 964/4885TUBB4A 296/4885TUBB 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.